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A
though type 2 diabetes is a hetero-
geneous condition encompassing
multiple metabolic and vascular al-
terations, it can be easily described as a
disease characterized by chronic hyper-
glycemia and increased cardiovascular
(CV) risk. Hyperglycemia is the diagnos-
tic criterion for diabetes, the target for an-
tidiabetic therapy, and, together with
A1C,themarkerofglycemiccontrol.Pro-
gressive worsening of glycemic control
has been described in type 2 diabetic pa-
tients irrespective of initial form of treat-
ment, leading the U.K. Prospective
Diabetes Study (UKPDS) investigators to
describe such changes as the “natural his-
tory” of the disease (1). Still, maintaining
goodglycemiccontroliscrucial,sinceitis
associated with marked reduction in the
risk of developing retinopathy, nephrop-
athy, and neuropathy in both type 1 (2)
and type 2 diabetic patients (1). But it is
CV disease that worsens long-term prog-
nosis in type 2 diabetes (3), to the point
that diabetes has been proposed as a CV
risk equivalent owed to the observation
that 10-year risk for major coronary
events approximates the risk in CHD in
patients without diabetes with previous
CV events (4), increased case fatality rate
after myocardial infarction, and worse
overall prognosis after CHD (5). In dia-
betic patients, even after correction for
known CV risk factors, the incidence of
myocardial infarction or stroke is two- to
threefold higher than in the nondiabetic
population, with a twofold increase in
riskofdeath(6),suggestingthatsomefea-
ture of diabetes must confer excessive
propensity toward CV disease.
Can this feature be hyperglycemia?
No better issue can be chosen for debate.
From an epidemiological point of view,
there is evidence that the risk of CV mor-
tality increases with the increase of
plasma glucose concentrations (7) and
A1C values (8). Moreover, multiple
atherogenic mechanisms have been iden-
tiﬁed that can be activated by hyperglyce-
mia (9). In spite of evident plausibility for
hyperglycemia as a CV risk factor itself,
intervention data remain controversial.
Even worse, results of recent large-scale
intervention trials such as ACCORD (10),
ADVANCE (11), and VADT (12) seem to
undermine the concept that strict glyce-
mic control may confer some protection
against CV disease in people with type 2
diabetes. This apparent paradox can only
be resolved by acknowledging the multi-
factorial nature of CV risk in diabetic pa-
tients (13). Many of these factors have
emerged in the UKPDS as well (14). In a
rankinganalysis,A1Cturnedouttobethe
third most important factor in determin-
ing CV risk in type 2 diabetic patients
(14). Therefore, antidiabetic drugs that
reduce blood glucose levels while exert-
ing some effect on CV risk factor should
be expected to provide beneﬁcial effects.
Still, the potential role that available oral
hypoglycemicagentsmayhaveonCVrisk
is an even more controversial issue. The
debateonthesafetyissueofglitazoneshas
not yet abated (15), so that assessing
whether oral hypoglycemic agents may
contribute to reduce CV morbidity/
mortality in type 2 diabetic patients be-
comes quite controversial and requires
carefulconsiderationofseveralimportant
issues. First of all, the ratio between the
blood glucose–lowering efﬁcacy of oral
hypoglycemic agents and their effects on
vasculature and the heart has to be
deﬁned.
INSULIN
SECRETAGOGUES — Sulfonylureas
have the longest record of use in diabetes
managementandhaveevolvedinthepast
50 years from ﬁrst-, second-, and third-
generation agents. Sulfonylureas enhance
insulin secretion upon binding with
-cell membrane receptors to close
SUR1/Kir6.2 channels. Blood glucose
lowering accounts for 0.5–2% A1C re-
duction but, because of ensuing hyperin-
sulinemia, weight gain and hypoglycemia
remain the main undesirable adverse ef-
fects. Last-generation sulfonylureas have
been claimed to exert some effect on lipid
proﬁle, C-reactive protein, tumor necro-
sis factor-, and plasma activator inhibi-
tor (PAI)-1 concentrations, but these
observations remain limited to small size
study with uncertain clinical implica-
tions. Available outcome studies are
largely based on ﬁrst- and second-
generation sulfonylureas and have led to
conﬂicting results. The University Group
Diabetes Project study (16) suggested in-
creased CV risk in patients treated with
tolbutamide, a ﬁrst-generation sulfonyl-
urea. These results have been widely crit-
icized on the basis of study design ﬂaws.
Moreover,someevidencesuggestsgreater
risk of mortality with ﬁrst-generation sul-
fonylureas compared with more recent
ones.
Muchdebatewasignitedbyamargin-
ally signiﬁcant 16% (P  0.052) reduc-
tion in fatal and nonfatal myocardial
infarction in the UKPDS where chlorpro-
pamide, glibenclamide, or glipizide were
usedasinitialtherapyinnewlydiagnosed
uncomplicated diabetic patients (1). Of
interest,however,thiseffectwasachieved
in the face of 4–5 kg body weight gain
during follow-up. Whether the ﬁnding
hastobeseenasapositiveoneornotmay
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mental effect of sulfonylureas on CV risk,
something that was much feared on the
basis of nonselective effects of these
agents on pancreatic and cardiac K-
ATPasechannels.Interactionwithcardiac
SUR2A/Kir6 channels can impair isch-
emic preconditioning, exposing patients
to increased CHD risk. On the other
hand, experimental results show that in-
hibition of sarcolemmal K-ATPase chan-
nels reduces the incidence of lethal
ventricular arrhythmias and improves
survival both during acute myocardial in-
farction and reperfusion (17). Moreover,
impairment of cardiac ischemic precon-
ditioning does not seem to occur with
more selective sulfonylureas such as
glimepiride and gliclazide. The latter has
been claimed to have some antioxidant
and antiplatelet aggregatory effect, and it
represents the base of the antidiabetic
treatment in the ADVANCE trial (11).
Thestudyshowedthatintensiveglycemic
control initiated with gliclazide but main-
tained by adding multiple hypoglycemic
agents as needed resulted in a nonsigniﬁ-
cant 6% reduction of major macrovascu-
larevents(hazardratio[HR]0.94,95%CI
0.84–1.06; P  0.32). Altogether, it is
possible to conclude that while no certain
cardioprotective effect can be attributed
to sulfonylureas, they do not seem to be a
matterofconcern,particularlyifthelatest
compounds are chosen. This view is sup-
ported by large retrospective analysis that
did not manage to identify a clear safety
signal. For instance, analysis of databases
ofDiabetesAuditandResearchinTayside
Scotland (DARTS) and Medicine and
Monitoring Unit (MEMO) (18) suggested
higher CV morbidity and mortality in the
sulfonylurea-treated patients compared
with those on metformin. On the con-
trary, Gulliford and Latinovic (19) failed
to show a signiﬁcant hazard ratio for all-
cause mortality in diabetic subjects
treatedwithsulfonylureascomparedwith
those treated with metformin (HR 1.06,
95% CI 0.85–1.31; P  0.616).
Meglitinides can be considered an
evolution of sulfonylureas, since they are
derived from nonsulfonylureic moiety of
sulfonylureas. Similar to the latter, repa-
glinide and nateglinide enhance insulin
secretion by binding the -cell sulfonyl-
ureareceptorbutatthelevelofadifferent
subunit,resultinginamorerapidonsetof
action, shorter half-life, and more physi-
ologic meal-related insulin response with
reduced risk of severe hypoglycemia.
Meglitinide treatment is associated with
0.5–0.8% A1C reduction. Small-size
studies have indicated a limited effect on
lipid proﬁle, PAI-1, lipoprotein(a), ho-
mocysteine,C-reactiveprotein,andinter-
leukin-6 concentration, similar, if not
slightlybetter,tothoseobservedwithsul-
fonylureas (20). Some emphasis has been
put on greater efﬁcacy of meglitinides
compared with sulfonylureas in control-
ling postprandial hyperglycemia, a pa-
rameter that has been associated with
increased CV risk. Twelve-month treat-
ment of diabetic patients with repaglinide
or glyburide was associated with similar
reduction of A1C (0.9%) but lower
postprandial glucose with the former
(148 vs. 180 mg/dl). Treatment with re-
paglinide was also associated with a
greaterproportionofpatientswithregres-
sion (0.020 mm) of carotid intima-
media thickness (52 vs. 18%, P  0.01)
(20).Still,nodataareyetavailableregard-
ing meglitinide effects on major CV
events. The Nateglinide and Valsartan in
Impaired Glucose Tolerance Outcomes
Research (NAVIGATOR) is a multina-
tional randomized double-blind placebo-
controlled forced titration, 2  2 factorial
design study designed to assess whether
treatment with either agent can prevent
developmentoftype2diabetesand/orre-
duce the risk of CV disease (21). The re-
sultsofthetrialsarenotexpecteduntilthe
end of year 2009.
Metformin
Insulin resistance is a central pathoge-
netic mechanism of type 2 diabetes,
which not only contributes to develop-
mentofhyperglycemiabutalsoconfersan
independent risk for CV disease. More-
over, insulin resistance plays an impor-
tant role in the development of many of
the disturbances encompassing the meta-
bolic syndrome (22). Therefore, insulin
sensitization is an attractive form of treat-
mentintheattempttoimprovemetabolic
control and reduce CV risk.
Metformin has been the only sensi-
tizer available for many years. It exerts a
prevalent effect on hepatic insulin sensi-
tivity, although some action is played on
skeletalmuscleandadiposetissueaswell.
Metformin can reduce A1C by 0.5–1.5%
and exerts beneﬁcial albeit modest effects
on traditional CV risk factors reducing
blood pressure (23), improving lipid pro-
ﬁle, and maintaining, if not lowering,
body weight due to a mild anorexiant ef-
fect. Many studies, although not all of
them, have shown that metformin can re-
duce oxidative stress and lipid peroxida-
tion, improve the pro-ﬁbrinolytic state by
reducing the circulating levels of PAI-1
andvonWillebrandfactor,hamperplate-
let aggregation, lower low-grade inﬂam-
mation, and improve endothelial
function. It is on the basis of these pleio-
tropiceffectsthatthepositiveoutcomesof
the UKPDS have been accounted for. Sec-
ondary analysis of 342 overweight dia-
betic patients treated with metformin
(Fig. 1) showed greater beneﬁcial effect
onalldiabetes-relatedendpoints,includ-
ing a 39% risk reduction for myocardial
infarction (P  0.01) compared with 951
patients treated with sulfonylureas or insu-
lin (24). Based on these results and retro-
spective analysis (19), a cardioprotective
effect of metformin has been claimed (25)
and metformin therapy has become a stan-
dard ﬁrst-line treatment in almost all na-
tional and international guidelines.
Thiazolidinediones
Thiazolidinediones(TZDs)areagonistsof
the peroxisome proliferator–activated re-
ceptor (PPAR)-, which enhances insulin
action primarily on the adipose tissue
with a favorable effect exerted on skeletal
muscle and liver as well (26). A bulk of
preclinical as well as small-size clinical
studies have focused on CV markers or
intermediate atherosclerosis outcomes to
providethebasisforpostulatingpotential
beneﬁcial effects of these drugs on the CV
risk of diabetic patients. Such a back-
ground has been extensively discussed in
a recent review by McGuire and Inzucchi
(27).
The typical A1C reduction associated
with the use of rosiglitazone and pioglita-
zone ranges between 1.0 and 2.0%, but
drug-speciﬁc changes in lipid proﬁle is
exertedbythetwodrugs.Inhead-to-head
comparison and meta-analysis of the
available studies (28), it was shown that
pioglitazone lowers triglycerides and in-
creases HDL cholesterol, with a neutral
effect on LDL cholesterol, while rosiglita-
zone treatment is associated with an in-
crease in HDL as well as total and LDL
cholesterol, with a neutral effect on trig-
lycerides. Besides these metabolic effects,
TZDs can lower blood pressure, reduce
microalbuminuria (29), and exert anti-
inﬂammatory and anti-oxidative action
along with an increase in adiponectin
levels.
As mentioned, positive effects have
been observed with respect to intermedi-
ate CV end points. For instance, TZD
treatmentisassociatedwithimproveden-
dothelial function, larger number of dia-
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intima-mediathickness,andlessre-stenosis
after coronary artery stent implantation.
More recently, the PERISCOPE study com-
pared the effect of pioglitazone and
glimepiride on progression of atheroscle-
rosis by intravascular ultrasonography in
type 2 diabetic patients and coronary ar-
tery disease (30). The trial showed a sig-
niﬁcantly lower rate of progression of
coronary atherosclerosis with pioglita-
zone than with glimepiride therapy.
Of a number of large-scale random-
ized controlled clinical trials, only the re-
sults from the PROspective pioglitAzone
Clinical Trial In macro-Vascular Events
(PROACTIVE) trial (31) and an interim
analysis of Rosiglitazone Evaluated for
Cardiac Outcome and Regulation of gly-
cemia in Diabetes (RECORD) (32) trial
have been so far published. The PROAC-
TIVE trial was a double-blind placebo-
controlled study performed in 5,238
diabetic patients with established macro-
vascular complications randomized to ei-
ther 45 mg/day pioglitazone or placebo
added to existing antidiabetic treatment.
Compared with placebo, pioglitazone
treatment was associated with lower A1C
(0.6%), triglycerides (21 mg/dl), sys-
tolic blood pressure (3 mmHg), and
higher HDL cholesterol (3.9 mg/dl). A
signiﬁcant reduction in the predeﬁned
secondary composite end point of all-
cause mortality, nonfatal myocardial in-
farction, and stroke (HR 0.84, 95% CI
0.72–0.98; P  0.027) was found, al-
though primary composite end point (all-
cause mortality, nonfatal myocardial
infarction, stroke, major leg amputation,
acute coronary syndrome, cardiac or leg
revascularization) did not reach statistical
signiﬁcance (31). A post hoc analysis in
patients with previous myocardial infarc-
tionalsoshowedthesigniﬁcantbeneﬁcial
effect of pioglitazone on the prespeciﬁed
endpointoffatalandnonfatalmyocardial
infarction (20% risk reduction; P 
0.045) and acute coronary syndrome
(37% risk reduction; P  0.035). The po-
tential reduction in atherosclerotic risk
associated with pioglitazone is supported
by the meta-analysis of 19 controlled
studies showing lower risk for a compos-
ite of death/myocardial infarction/stroke
(HR0.82,95%CI0.72–0.94;P0.005)
(33).
No completed long-term trials in dia-
betic patients are currently available for
rosiglitazone. The RECORD trial has so
farrecordednostatisticallysigniﬁcantdif-
ference in risk of hospitalization (HR
1.08, 95% CI 0.89–1.13; P  0.43) or
mortality (HR 0.83, 95% CI 0.67–1.27;
P  0.46) due to CV cause (32). The re-
sults have been essentially conﬁrmed by
the ﬁnal study report (34). The interim
analysis prompted by the publication of
Nissen meta-analysis (35) reporting a sig-
niﬁcant increase in the risk of myocardial
infarction (odds ratio 1.43, 95% CI 1.03–
1.98; P  0.03) and a nonsigniﬁcant in-
crease in the risk of CV mortality (odds
ratio 1.64, 95% CI 0.98–2.74; P  0.06).
That report generated much discussion
duetolimitationsinthestatisticalanalysis
(27)andtriggeredfurtherreassessmentof
available data leading to the uncertain ef-
fectofrosiglitazoneontheriskofmyocar-
dial infarction and death from CV causes
(36).
Irrespective of the safety signal on
myocardial infarction risk, both TZDs
have been shown to cause weight gain,
ﬂuid retention, and edema and poten-
tially worsen incipient congestive heart
failure (CHF). In the PROACTIVE study,
hospitalization for CHF occurred in 5.7%
of patients treated with pioglitazone ver-
sus 4.1% treated with placebo (P 
0.007), with no evident increase in heart
failure–associated mortality (25 [0.96%]
vs. 22 [0.84%] cases) (31). In the
RECORD study, incidence of hospitaliza-
tion for CHF was higher in rosiglitazone-
treated patients than in the control group
(1.7 vs. 0.8%; P  0.006) (32).
With such a contradictory scenario,
how can we then reconcile positive and
negative signals for efﬁcacy and safety of
TZDs on CV risk? There is no obvious
answer to that, but several controlled tri-
als in patients with different CV risk are
still ongoing. While these studies should
be carefully monitored, their results are
much needed to gain a better assessment
of the real impact of TZDs on the CV risk
of type 2 diabetes. Still, a lesson is already
available. Careful selection of patients in-
deed not only may reduce the risk of se-
vere adverse events (in particular, CHF)
(37), but it may also identify those indi-
viduals in whom greater metabolic and
CV beneﬁt may be ensured.
-Glucosidase inhibitors
The -glucosidase inhibitors act by
blocking the action of intestinal -gluco-
sidase,whichhydrolyzesdiet-derivedoli-
Figure 1—Effect of sulfonylurea (Sulf) and metformin versus conventional blood glucose control on micro- and macrovascular diabetes complica-
tions in the UKPDS. Adapted from Ref. 1 for sulfonylureas or insulin (Ins) data and from Ref. 24 for metformin data.
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consequence, they slow carbohydrate di-
gestion and absorption and reduce post-
prandial glucose excursion. This glucose-
lowering effect results in 0.5–0.8% A1C
reduction. A recent meta-analysis by
Hanefeld et al. (38) conﬁrms that along
with improved glycemic control, acar-
bose also can lower triglyceride levels,
body weight, and systolic blood pressure.
When used in people with impaired glu-
cose tolerance, acarbose slowed progres-
sion of carotid intima-media thickness
with a 50% reduction in its annual in-
creasecomparedwithplacebo.Moreover,
in the STOP-NIDDM trial, a large multi-
center double-blind placebo-controlled
study performed to assess prevention of
diabetes by acarbose in subjects with im-
paired glucose tolerance, a signiﬁcant re-
duction in risk of myocardial infarction
(HR 0.09, 95% CI 0.01–0.72; P  0.02)
and a 34% relative risk reduction in the
incidence of new cases of hypertension
(HR0.66,95%CI0.49–0.89;P0.006)
wasobserved(39).Althoughtheseresults
do require further conﬁrmation (40),
mechanisms that may account for this
positive effect have been investigated
(41). A major effect is attributed to pre-
vention of a rapid raise in postprandial
hyperglycemia, resulting in reduced oxi-
dative stress and inﬂammatory response,
ﬁbrinogen concentration, macrophage
adhesiontoendothelium,andendothelial
function. From this point of view, of in-
terest are the similarities of the results ob-
tained with metiglinides, i.e., another
therapeutic approach associated with
moreeffectivepostprandialglycemiccon-
trol. Both treatments have been shown to
improve regression of carotid intima-
media thickness (20).
NEW DRUGS— New hypoglycemic
agents have been recently introduced for
treatment of type 2 diabetes. For these
new agents, careful assessment of CV ef-
fects is still required, but they are worth
mentioning because of some intriguing
features. From a better understanding of
the physiologic meaning of the entero-
pancreatic axis, incretin-based therapy
has been made available either as inject-
able GLP-1 analogs (exenatide, lira-
glutide) or inhibitors of dipeptidyl
peptidase-4 (DPP-4), the enzyme respon-
sible for GLP-1 degradation. In clinical
trials, when adding exenatide to existing
oral antidiabetic therapy, results showed
an improvement of 	1% of A1C, in asso-
ciation with a decrease in body weight.
Preliminary studies have suggested con-
comitantimprovementsinCVriskfactors
(HDL, triglyceride, and total cholesterol
levels as well as blood pressure) (42). Of
interest, experimental data have shown
that GLP-1 may enhance recovery of left
ventricular function after transient coro-
nary artery occlusion in the isolated rat
heart model, possibly due to improved
glucose uptake by cardiomyocytes and
activation of anti-apoptotic signaling
pathways. In the same experimental
model, exenatide was shown to reduce
post-ischemic infarct size and improve
mechanical performance. GLP-1 infusion
over 72 h after successful primary coro-
nary intervention in patients with acute
myocardial infarction and depressed left
ventricular ejection fraction (40%) was
associated with signiﬁcant improvement
in left ventricular ejection fraction (29 

2to39
2%;P0.01)andamelioration
in global and regional wall motion (43).
More recently, the same investigators in-
fused GLP-1 over a 5-week period in pa-
tients with advanced heart failure and
compared outcomes with those of pa-
tients on standard therapy. In the former,
left ventricular ejection fraction increased
along with VO2max and quality-of-life
score. These results suggest that GLP-1
mimetics/analogs may be a suitable can-
didate in clinical management of diabetic
patients with coronary heart disease or
heart failure (42). However, more exten-
sive data from clinical trials and judicious
postmarketing clinical surveillance are
necessary to appropriately evaluate po-
tential CV risk-to-beneﬁt ratio.
Oral inhibitors of DPP-4 increase the
plasma concentrations of the biologically
active form of endogenously secreted in-
cretins.TheﬁrstavailableDPP-4inhibitor
was sitagliptin, followed by vildagliptin,
while several others are in the advance
stage of clinical development. Clinical
studies suggest these agents are safe and
tolerable (44). Of interest, the risk for hy-
poglycemia, a known trigger factor for
acute CV events, is very low, whereas
body weight neutrality may be of value in
overweight/obesetype2diabeticpatients.
Beside these nonselective effects, the di-
rect impact of these agents on CV disease
is still unknown, but long-term studies
are under development to address the
issue.
Rimonabant, the ﬁrst selective endo-
cannabinoid (CB)-1 receptor antagonist,
has been extensively investigated in the
Rimonabant in Obesity (RIO) program.
Rimonabant consistently reduces body
weight, waist circumference, triglycer-
ides, blood pressure, insulin resistance,
and C-reactive protein levels and in-
creases HDL cholesterol concentrations
in both nondiabetic and type 2 diabetic
overweight/obese patients (45,46). How-
ever, the drug has been discontinued
from the market because of its adverse
events.
HYPOGLYCEMIC AGENTS
REDUCE CARDIOVASCULAR
EVENTS/MORTALITY IN
TYPE 2 DIABETES: IS THERE
AN AFFIRMATIVE
RESPONSE?— Althoughquicklyre-
viewed, it cannot be denied that the avail-
able data are far from providing an
evidence-based solid answer to our ques-
tion. For many of the agents currently in
use, randomized controlled trials are not
available and when available are limited.
Perhaps the best example is metformin.
Generally adopted as a preferred ﬁrst-line
(47) treatment, it has been recently pro-
posed that contra-indication to metform-
in’s use should be relaxed to allow more
patients to beneﬁt from its multiple ef-
fects, including those on CV risk (25).
Still, all this is based in a small cohort of
the UKPDS (24) including 342 patients
(Fig. 1), quite a small sample compared
with more recent large-scale trials unable
to support clear-cut CV beneﬁt. Even
when large trials are available, their inter-
pretation and comparison is not a simple
one.Studypopulationsmayindeeddiffer.
For instance, while in the UKPDS (1,24),
newly diagnosed type 2 diabetic patients
with no CV complications were enrolled,
and high-risk individuals were included
in the University Group Diabetes Project
(16) or in the PROactive (31) studies.
Treatment of type 2 diabetes has evolved
over the time, and it is now widely ac-
cepted that multifactorial intervention is
required to effectively reduce CV risk, as
clearlydemonstratedbytheSteno2study
(48). The use of statins and drugs inter-
fering with the renin-angiotensin system,
as well as anti-platelet treatment, is now-
adays expectedly more common. Because
of this, results obtained with a trial per-
formed 10 years ago may not be directly
comparable to those concluded today or,
even more difﬁcult, to those to be com-
pleted tomorrow. Type 2 diabetes is a
very heterogeneous chronic condition in-
cluding young and old individuals, with
short or long duration of diabetes, with
andwithoutmicro-and/ormacrovascular
complications, with and without comor-
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neity.Inlightofsuchacomplexpicture,it
looks more appropriate that antidiabetic
therapy to be individualized with respect
torisk-to-beneﬁtratio.TZDsandCHFisa
typical example of the importance of pa-
tient selection, highlighting the need for
safe procedure as well as safe drugs (37).
This becomes even more relevant in light
that, due to the chronic and progressive
natureofdiabetesandthedevelopmentof
the disease at a younger age, multiple hy-
poglycemic agents will be combined to
ensure glycemic control. Even less evalu-
ationiscurrentlyavailableonthemultiple
permutations that the availability of six
classes of oral hypoglycemic agents may
generate. Thus, the beneﬁcial effects of
metformin shown in the UKPDS were
completely lost when the drug was used
in combination with sulfonylureas (1), a
ﬁnding that has been both conﬁrmed and
ruled out (49) in subsequent retrospec-
tive analysis. In the ACCORD (10), AD-
VANCE (11), and VADT (12) trials,
treating-to-target required greater expo-
sure to drugs from every class and more
frequent changes in the dose or the num-
ber of drugs used. Still, the three trials
ended up with different results: modest
reduction of events with increased mor-
tality in the former in intensively treated
diabetic patients. The explanation for ex-
cess of mortality in the face of a reduced
number of CV events in the ACCORD
study remains elusive, but initial analysis
could not identify association with any of
the oral hypoglycemic agent or combina-
tion used. Rather, these trials may return
ourattentiontothevalueofglycemiccon-
trol rather than to the agent(s) used to
achieve and maintain it. Although some
cautionmaybewarrantedinhigh-riskCV
patients in lowering A1C to target values
(6.5%) (50), the need for good glycemic
control in low-risk patients remains
highly recommended (51). Because CV
risk is likely to progress with duration of
the disease, it is in the early stage of dia-
betes that strict glycemic control should
be attained. Prevention of worsening in
glycemiccontrolmayalsoresultinanim-
provement in multiple metabolic alter-
ations. As shown in Fig. 2, the prevalence
of metabolic syndrome in type 2 diabetes
increaseswiththeworseningofA1C(52).
Good glycemic control as represented by
A1C levels as close to the normal range
from the time of diagnosis has been
showntoreducetheriskofmicrovascular
complications—still a major burden to
the patient and society (53). With respect
to this, it should be kept in mind that
diabetic microangiopathy is most likely a
diffuse process involving cardiac micro-
circulation as well affecting coronary re-
serve,i.e.,amaindeterminantofthepost-
ischemic necrotic area. Moreover, a
typical microangiopathic complication
suchasdiabeticretinopathyishighlypre-
dictive of CV outcomes. Maintenance of
near-normal glycemic control from the
early stage of the disease would require
individualized therapies, or at least ac-
curate balance of efﬁcacy and safety of
oral hypoglycemic agents. Increasing
the availability of such agents, as it oc-
curred in the past few years, will then
require a major effort in identifying the
most durable form of treatment. If this
could be achieved from the time of di-
agnosis, then maybe oral hypoglycemic
agents will exert their CV protective
effect.
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